Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.

To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.

Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.

Manufacturing authorisations and/or distribution authorisations of medicines and registrations of active pharmaceutical ingredients are no longer automatically sent in paper format by post to the marketing authorisation holder. The FAMHP is now sending these documents in digital format by e-mail. Marketing authorisation holders can still request paper versions.

To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.

Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.